• Targeted Therapies for Bone Regeneration

    We are commercializing a small molecule-based osteoinductive platform technology to develop bone growth products that activate a novel molecular pathway.

     

    Discovered serendipitously, ZetaGen's products have the potential to transform the treatment of bone-related injuries, procedures and diseases to deliver better outcomes for patients, doctors and payors.

  • OUR STORY

    A Serendipitous
    Discovery

    An accidental injection led to the identification of a novel molecular pathway that has the ability to address several unmet clinical needs. After multiple years of research, the ZetaGen team has characterized the pathway’s novel mechanism of action.
     
    By controlling cellular division using this novel target, ZetaGen has the potential to apply the benefits of this technology to several different areas of patient need.
  • Technology

    Benefits

    Initial data indicate this novel pathway has the potential to offer a suite of advantages not observed by other products on market, including:

    Bone Growth

    Initial data show bone generation better than biologic growth factors

    Anti-Tumorigenic

    Inhibition of cancer growth via a known p21 mechanism

    Anti-Osteolytic

    Down-regulation of osteoclasts reduces bone destruction

    Small Molecule-Based

    Our products will utilize small molecule components that are significantly more cost-effective to manufacture relative to biologic comparators

    Safe Components

    Components of our products have well-established clinical safety profiles

    New Populations

    The technology has the potential for wider use compared to existing therapies due to its unique safety profile

  •  

    Our Science

    A novel pathway for bone growth

     

    PDF 1.9 mb

  • ABOUT US

    Team

    We believe in identifying and pursuing optimal therapeutic solutions - no matter how unconventional - by building a learning organization that maximizes outcomes for people, investors and society.

    David Tischler

    CEO and Cofounder

    David’s background has been primarily focused on building and financing early stage life science and medical device companies. Prior to ZetaGen, he served as acting CEO of DigiSight Technologies, a venture-backed ophthalmology disease management company founded out of Stanford University. David was also a product manager at Castlight Health (NYSE: CSLT). Previously, he worked as an associate at Venzyme Venture Catalyst located in the Boston area and as the Due Diligence Chair for Mass Medical Angels. David holds a BS in Biology from the University of Michigan and an MBA from the UC Berkeley-Haas School of Business.

    Bryan Margulies, PhD

    CSO and Cofounder

    Dr. Margulies was formerly an assistant professor of orthopedics, cell biology and pharmacology at SUNY-Upstate. His research focuses on stem cell modulation to promote bone formation in all practice areas including bone sarcoma. He obtained his PhD, MS and BS in bioengineering from Syracuse University and trained at the University of Pennsylvania in the College of Veterinary Medicine. Dr. Margulies was an NIH NRSA Fellow, a Mazess Student Fellow and has over 25 publications.

    Nikhil Thakur, MD

    Cofounder and Board Director

    Dr. Thakur is the Director of the Spine Center at Lawrence General Hospital, a Harvard affiliate. He specializes in adult spine reconstructive surgery and has over a decade of orthopedic surgical experience. He has won multiple awards for his orthopedic research and has over 25 publications. Dr. Thakur received his MD from Geisel School of Medicine at Dartmouth and completed his fellowship training in trauma from Brown University and in spine surgery from Emory University.

  • Supporters

    We are grateful for the support we have received to date from several groups including:

  • Contact Us

    Thanks for visiting ZetaGen. If you are interested in our work and would like to keep track of our progress, please send us a note.